Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a derivative of amantadine. It is used in the treatment of Alzheimer's disease, parkinsonism and central spasticity and other brain injuries or comatose states. Oral administration once or twice daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its low molecular weight and low binding to plasma proteins would facilitate its excretion in breast milk, while its high volume of distribution would make it difficult.
For some authors it is an expendable product, with a negative risk/benefit ratio. (Prescrire 2018)
It may cause drowsiness, dizziness, hypertension, dyspnea, constipation, headache, and liver function abnormalities. (AEMPS 2020)